Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back

References

• Jabbour E, Kantarjian H. Chronic myeloid leukemia:2012 update on diagnosis, monitoring, and management. Am J Hematol 2012;87:1037–1045.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031–1037.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038–1042.
   PubMed Web of Science ®Google Scholar
• Gleevec [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2013.
   Google Scholar
• Deininger M, O’Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009;114(Suppl. 1): Abstract 1126.
   Google Scholar
• Ghadyalpatil N, Banawali S, Kurkure P, et al. Efficacy and tolerability of imatinib mesylate in pediatric chronic myeloid leukemia in a large cohort: results from a tertiary care referral center in India. J Clin Oncol 2009;27(15 Suppl.): Abstract 10047.
   Web of Science ®Google Scholar
• Razmkhah F, Razavi M, Zaker F, et al. Hematologic and molecular responses to generic imatinib in patients with chronic myeloid leukemia. Lab Med 2010;41:547–550.
   Web of Science ®Google Scholar
• Gogtay J, Chahchad S, Jadhav S, et al. Response to the case report by Mattar: generic imatinib (Imatib, Cipla) in a patient with chronic myeloid leukemia in chronic phase. Int J Hematol 2010;92: 772–773.
   PubMed Web of Science ®Google Scholar
• Chouffai Z. Hematologic relapse after 2 years on a non-authorized copy version of imatinib in a patient with chronic myeloid leukemia in chronic phase: a case report. Case Rep Oncol 2010;3:272–276.
   PubMedGoogle Scholar
• Goubran HA. Failure of a non-authorized copy product to maintain response achieved with imatinib in a patient with chronic phase chronic myeloid leukemia: a case report. J Med Case Rep 2009;3:1–3.
   Google Scholar
• Asfour IA, Elshazly SA. Changing therapy from Glivec to a “copy” imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports. Cases J 2009;2:9342.
   PubMedGoogle Scholar
• Mattar M. Failure of copy Imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leukemia in chronic phase. Int J Hematol 2010;91:104–106.
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349:1423–1432.
   PubMed Web of Science ®Google Scholar
• Torres A, Navarro JR, Untama J, et al. 5 year experience in chronic phase-chronic myeloid leukemia treated with imatinib copy drugs in a Peruvian hospital. Blood 2011;118(Suppl. 1): Abstract 4449.
   Google Scholar
• Kantarjian H, O’Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012;119:1981–1987.
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358–3363.
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251–2259.
   PubMed Web of Science ®Google Scholar
• Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012;26:2197–2203.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260–2270.
   PubMed Web of Science ®Google Scholar
• Tasigna [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2014.
   Google Scholar
• Sprycel [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; June 2013.
   Google Scholar
• Saglio G, Hochhaus A, Hughes TP, et al. ENESTnd update: nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and Sokal risk at diagnosis on long-term outcomes. Blood 2013;122(Suppl. 1): Abstract 92.
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876–880.
   PubMed Web of Science ®Google Scholar
• Donato NJ, Wu JY, Stapley J, et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004;64:672–677.
   PubMed Web of Science ®Google Scholar